The so-called “double-edged sword” of up-regulating the kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid 2-related factor 2 (Nrf2) pathway must, however, be considered when applied to patients with tumors or other actively growing cancers. Here, KEAP1 is linked to cancer.